Stocks Little Changed After Dow Snaps Streak
Stock futures were little changed Thursday after the Dow Jones Industrial Average snapped a four-day win streak.Futures for the 30-stock index gained 22 points to 42,522.Futures for the S&P 500 index edged higher 0.25 points to 5,981.25.Futures for the NASDAQ dipped 7.75 points to 21,758.75. The three major U.S. indexes are tracking for gains so far this week. The S&P 500 is up 1%, while the Dow has added 0.4%. The tech-heavy NASDAQ has jumped 1.8% week to date.Analysts at Jefferies downgraded shares in Chewy Inc. to hold from buy. It did raise its price target by $2 to $43, but that still implies downside of 9%.Private sector payrolls rose by just 37,000 in May on Wednesday, coming in sharply below the Dow Jones forecast for 110,000 and raising investors’ worries about the softening job market and the impact on the economy. Those concerns weighed on the major averages during the session, too.Still, the market’s recent gains — which have been powered by a surge in technology stocks — coupled with a blowout first-quarter earnings season have revived sentiment on Wall Street. Still, investors remain cautious that further pain could be ahead due to the Trump administration’s tariffs.In Japan, the Nikkei 225 index fell 0.5% Thursday, while in Hong Kong, the Hang Seng bounced 1.1% Oil prices eked up 11 cents to $62.96 U.S. a barrel. Gold prices grew $21.50 to $3,420.70 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


